PCV16 ROSUVASTATIN IS MORE COST-EFFECTIVE COMPARED TO ATORVASTATIN AND SIMVASTATIN FOR HYPERLIPIDEMIA MANAGEMENT IN HIGH-RISK PATIENTS IN ROUTINE CLINICAL PRACTICE
Keyword(s):
2013 ◽
Vol 167
(4)
◽
pp. 1380-1384
◽
Keyword(s):
2008 ◽
Vol Volume 4
◽
pp. 1407-1416
◽
Keyword(s):
2017 ◽
Vol 13
(2)
◽
pp. 155-163
◽
Keyword(s):
Keyword(s):
Keyword(s):
2013 ◽
Vol 89
(Suppl 1)
◽
pp. A341.3-A341
Keyword(s):
Keyword(s):